PhaseBio Pharmaceuticals Inc. (PHAS) PT Lowered to $17 at Stifel
Tweet
Share
E-mailGet Alerts PHAS Hot Sheet
Price: $0.07 --0%
Rating Summary:
2 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 3
Rating Summary:
2 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 3
Join SI Premium – FREE
Stifel analyst Adam Walsh lowered the price target on PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) to $17.00 (from $20.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Douglas AG (DOU:GR) to Sell
- Sampo Oyj (SAMPO:FH) (SAXPY) PT Raised to EUR11.20 at Berenberg
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
StifelSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
